DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

Phase 2

Not yet recruiting

Conditions: Heart Failure

Interventions: Drug: CDR132L
Drug: Placebo

First Posted Date: 2025-05-19

Last Posted Date: 2025-05-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT06979375

Locations: 🇦🇺
Victorian Heart Hospital, Clayton, Victoria, Australia
🇦🇺
Fiona Stanley Hospital Cardiology, Murdoch, Western Australia, Australia
🇨🇿
Fakultní nemocnice u sv. Anny v Brně, Brno, Czechia

and more 72 locations

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Phase 2

Not yet recruiting

Conditions: Heart Failure

Interventions: Drug: CDR132L
Drug: Placebo

First Posted Date: 2025-05-19

Last Posted Date: 2025-05-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT06979362

Locations: 🇮🇳
Sengupta Hospital and Research Institute, Nagpur, Maharashtra, India
🇺🇸
Duke University_Durham, Durham, North Carolina, United States
🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States

and more 80 locations

Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam

Conditions: Obesity
Obesity-related Complications

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1165

Registration Number: NCT06843473

Locations: 🇮🇳
AIIMS,Delhi, New Delhi, Delhi, India
🇵🇰
National Hospital Lahore, Lahore, Pakistan
🇵🇭
Asian Hospital and Medical Center, Metro Manila, San Juan, Philippines

and more 1 locations

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

Phase 1

Recruiting

Conditions: Healthy Volunteers
Hyperuricemia

Interventions: Drug: NNC4004-0002
Drug: Placebo

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT06859073

Locations: 🇺🇸
PAREXEL Intl - EPCU-Baltimore, Baltimore, Maryland, United States

SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data

Completed

Conditions: Type 2 Diabetes Mellitus (T2D) and Chronic Kidney Disease (CKD)

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 110074

Registration Number: NCT06769646

Locations: 🇮🇳
Novo Nordisk Investigational site, Bangalore, India

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

Phase 1

Recruiting

Conditions: Healthy Volunteers
Hepatic Steatosis

Interventions: Drug: NNC0581-0001
Drug: Placebo (NNC0581-0001)

First Posted Date: 2025-03-24

Last Posted Date: 2025-03-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT06891365

Locations: 🇬🇧
Parexel CPRU, Level 7, Harrow, United Kingdom

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

Completed

Conditions: Overweight
Obesity
Atherosclerotic Cardiovascular Disease (ASCVD)

First Posted Date: 2025-03-13

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45456

Registration Number: NCT06874751

Locations: 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States

Cities for Better Health Childhood Obesity Prevention Initiative

Conditions: Obesity

First Posted Date: 2025-03-04

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36000

Registration Number: NCT06855563

Locations: 🇧🇷
Novo Nordisk, Campinas, Brazil
🇿🇦
Novo Nordisk Investigational Site, Johannesburg, South Africa

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Not yet recruiting

Conditions: Haemophilia A, Haemophilia B

Interventions: Drug: Concizumab

First Posted Date: 2025-02-18

Last Posted Date: 2025-04-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT06831734

Locations: 🇯🇵
Chiba university hospital_Pediatrics, Chiba, Japan
🇯🇵
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa, Japan
🇯🇵
Nanbu Medical Center & Children's Medical Center, Okinawa, Japan

and more 2 locations

A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing

Phase 1

Recruiting

Conditions: Overweight
Obesity

Interventions: Drug: NNC0487-0111
Drug: Placebo (NNC0487-0111)

First Posted Date: 2025-02-11

Last Posted Date: 2025-03-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT06820476

Locations: 🇨🇳
Jinan Central Hospital, Ji'Nan, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy